Clinical approval of kangbaoruiadinium bromide, a subsidiary of Wuxi apptec
-
Last Update: 2015-04-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On April 14, 2015, adinium powder inhalant was approved for clinical use in China, and Shanghai kangbaorui medical clinical research Co., Ltd., a subsidiary of Yao mingkant, a cro company, applied Adelbromide is a long-acting muscarinic antagonist (Lama), which improves airflow by relieving the muscles around the large airway The drug was approved by FDA in July 2012 (trade name: tudorza pressair) for long-term maintenance treatment of bronchospasm (narrowing of pulmonary airway) related to chronic obstructive pulmonary disease (COPD) Adibam was first developed by forest laboratory In the first half of 2014, atvis purchased forest laboratory with us $25 billion In early 2015, AstraZeneca purchased the respiratory product line of atvis, and this respiratory product fell into AstraZeneca's bag The respiratory products added to the sales volume of AstraZeneca together with adelbromide also include rofustist, the PDE4 inhibitor of AstraZeneca In addition, AstraZeneca also obtained the right to develop the fixed dose compound preparation of adelbromide and formoterol As a result, AstraZeneca's respiratory product portfolio is becoming richer At present, adibam has been approved for clinical use in China, but the fixed dose combination of adibam and formoterol with better therapeutic effect has not been approved for clinical use in China.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
